2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

To help you in your search, three Fool.com contributors have pulled together reports on a few opportunities they think are ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

The added benefit is that AbbVie is a "Dividend King," which means it has consistently paid and increased dividends for the ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That' ...

With a current dividend yield of 3.2%, AbbVie Inc. ABBV was a key stock in the investor’s portfolio earning $4,800 per month. The stock has gained about 42% over the past year. AbbVie has raised ...

US central bank lowered rates by another 25 basis points on Thursday. AbbVie, Chevron, and Elf Beauty could benefit from ...